$HDSN

Hudson Technologies (HDSN) Signs Icorium Deal. Can Better Refrigerant Recycling Lift Margins?

Hudson Technologies (HDSN) partnered with Icorium to develop better refrigerant recycling tech. Q2 revenue rose 8% to $78.3M, but gross margin fell to 26% from 31%. The deal aims to improve recovery yields and margins, but costs and timelines remain unclear.

Original reporting
Published Sep 24, 2026, 10:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 11:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Hudson Technologies (HDSN) Signs Icorium Deal. Can Better Refrigerant Recycling Lift Margins? — source image
Decision brief

The 30-second read

$HDSNNeutralLow
01

Why it matters

The Icorium agreement offers a path to higher recovery yields, but lacks concrete cost or timeline data.

02

Market read

A new technology partnership for a niche industrial segment; limited immediate price impact.

03

What to watch

Potential regulatory or environmental incentives could enhance value.

Relevance 5/10Novelty 6/10Timing: post-announcement

Background

Hudson Technologies reported Q2 revenue of $78.3M with declining gross margin, prompting the search for efficiency gains.

Company-level read

Ticker impact

$HDSNNeutralMedium confidence
Context

Hudson Technologies announced a joint development agreement with Icorium to commercialize extractive distillation technology.

Expected impact

Modest upside potential if commercial yields are disclosed.

Evidence & confidence

No financial terms or timeline were provided, limiting immediate impact.

Market effects

May signal broader interest in refrigerant recycling technologies.

Limited to U.S. industrial recycling sector.

Low global impact at this stage.

Counterpoint

Without disclosed economics, the deal may not translate into margin improvement.

Key entities

  • Hudson Technologies, Inc.

    NASDAQ-listed industrial recycling firm.

  • Icorium

    Provider of extractive distillation technology.

Related articles

$HDSNMedAI 8/10

Hudson Technologies (HDSN) Q2 2026 Earnings Call Transcript

Hudson Technologies (HDSN) reported Q2 2026 revenue of $78.3 million, up 8% year over year, on 12% higher sales volume. Average refrigerant prices fell 6%, pressuring gross margin to 26% from 31% in Q2 2025. Net income was $4.9 million ($0.12/share) versus $10.2 million ($0.23) a year earlier. Full-year gross margin guidance was revised to low-to-mid 20%.

$HDSNMed

Hudson Technologies Q2 Earnings Call Highlights

Hudson Technologies (NASDAQ:HDSN) reported Q2 revenue of $78.3 million, up 8% year over year, with sales volume up 12% but average refrigerant selling price down 6%. Gross margin fell to 26% from 31% a year earlier. The company revised its FY2026 gross-margin target to the low-to-mid-20% range and said the Defense Logistics Agency re-awarded a five-year $210 million contract.

$HDSNMed

Hudson Technologies (NASDAQ:HDSN) Surprises With Q2 CY2026 Sales

Hudson Technologies (NASDAQ:HDSN) reported Q2 CY2026 revenue of $78.35 million, up 7.5% year on year and 5.6% above Wall Street estimates, according to the company. GAAP EPS was $0.12, below consensus and down from $0.23 a year earlier. Management cited selling-season growth despite HFC price weakness and inflation. Shares fell 1.5% to $6.12 after the release.

$HDSNMed

HUDSON TECHNOLOGIES REPORTS SECOND quarter 2026 reSults

HUDSON TECHNOLOGIES INC /NY (HDSN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 HUDSON TECHNOLOGIES REPORTS SECOND quarter 2026 reSults Second quarter revenue grew 8% driven by strong volume Posts trailing twelve month double-digit volume growth Operations fully restored at tornado impacted facility Announces Icorium partnership Maintains unleve

$BDXLowAI 8/10

BD reports nine-month AGILITY trial data for Revello stent

Becton, Dickinson and Company (BD) reported nine-month data from the AGILITY trial of its Revello Vascular Covered Stent, showing a 2.8% failure rate for the primary endpoint in iliac artery disease patients. The trial met its safety and effectiveness goals, with 97.2% primary patency and 98.3% freedom from revascularization. The stent is CE-marked in Europe but remains investigational in the US. BD aims to further characterize the stent's performance as follow-up continues.